1-hydroxymethylmidazolam has been researched along with midazolam in 159 studies
| Studies (1-hydroxymethylmidazolam) | Trials (1-hydroxymethylmidazolam) | Recent Studies (post-2010) (1-hydroxymethylmidazolam) | Studies (midazolam) | Trials (midazolam) | Recent Studies (post-2010) (midazolam) |
|---|---|---|---|---|---|
| 163 | 46 | 49 | 9,834 | 3,191 | 3,301 |
| Protein | Taxonomy | 1-hydroxymethylmidazolam (IC50) | midazolam (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 2.7427 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (9.43) | 18.7374 |
| 1990's | 32 (20.13) | 18.2507 |
| 2000's | 53 (33.33) | 29.6817 |
| 2010's | 49 (30.82) | 24.3611 |
| 2020's | 10 (6.29) | 2.80 |
| Authors | Studies |
|---|---|
| Belas, F; Chaudhary, AK; Cvetkovic, M; Dempsey, PJ; Fromm, MF; Kim, RB; Leake, B; Roden, DM; Roden, MM; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Katoh, M; Nakajima, M; Yamazaki, H; Yokoi, T | 1 |
| Breimer, DD; Cohen, AF; Danhof, M; Mandema, JW; Tuk, B; van Steveninck, AL | 1 |
| Driessen, JJ; Guelen, PJ; Vree, TB | 1 |
| Bastide, P; Chopineau, J; Sautou, V; Terrisse, MP | 1 |
| Dayer, P; Gascon, MP | 1 |
| Ellinwood, E; Linnoila, M; Marsh, G | 1 |
| Dayer, P; Gascon, MP; Waldvogel, F | 1 |
| Dixon, JS; Park, GR; Shelly, MP | 1 |
| Dawling, S; Manara, AR; Park, GR | 1 |
| Sunzel, M | 1 |
| Cano, JP; Coassolo, P; Crevat-Pisano, P; Dragna, S; Francois, G; Granthil, C | 1 |
| Blumenthal, HP; Bornemann, LD; Colburn, WA; Crews, T; Min, BH; Patel, IH; Rees, MM | 1 |
| Bornemann, LD; Chen, SS; Crews, T; Patel, IH; Twardak, S | 1 |
| Finster, M; Kaine, CJ; Kuhnert, BR; Santos, AC; Syracuse, CD | 1 |
| Eichelbaum, M; Kassai, A; Klotz, U; Toth, G | 1 |
| Blackett, A; Cromarty, JA; Dhillon, S; Horne, R; Richards, G | 1 |
| Clausen, TG; Crevoisier, C; Dixon, JS; Hansen, PB; Larsen, F; Rasmussen, SN; Wolff, J | 1 |
| Mendel, L; Park, GR; Shelly, MP | 1 |
| Eichelbaum, M; Klotz, U; Mikus, G; Zekorn, C | 1 |
| Arendt, RM; Garland, WA; Greenblatt, DJ | 1 |
| Arts, TH; Fragen, RJ; Reekers-Ketting, JJ; Vree, TB | 1 |
| Bauer, TM; Ha, HR; Haberthür, C; Haefeli, WE; Hunkeler, W; Ritz, R; Scollo-Lavizzari, G; Sleight, AJ | 1 |
| Ring, BJ; Wrighton, SA | 1 |
| Barr, DM; Hartwell, PS; Kunze, KL; Marsh, CL; McVicar, JP; Podoll, TD; Raisys, VA; Shen, DD; Thummel, KE; Trager, WF | 1 |
| Bacchi, CE; Barr, DM; Kunze, KL; Marsh, CL; McVicar, JP; Perkins, JD; Podoll, TD; Shen, DD; Thummel, KE; Trager, WF | 1 |
| Donati, F; Mastey, V; Panneton, AC; Varin, F | 1 |
| Gorski, JC; Hall, SD; Jones, DR; VandenBranden, M; Wrighton, SA | 1 |
| Ha, HR; Kneer, J; Rentsch, KM; Vonderschmitt, DJ | 1 |
| Binkley, SN; Ring, BJ; Roskos, L; Wrighton, SA | 1 |
| Chen, J; Follath, F; Freiburghaus, AU; Ha, HR; Leuenberger, PM | 1 |
| Kunze, KL; O'Shea, D; Paine, MF; Perkins, JD; Shen, DD; Thummel, KE; Wilkinson, GR | 1 |
| Miller, E; Navapurkar, V; Park, GR | 1 |
| Barr, DM; Gillies, BS; Kunze, KL; Marsh, CL; McVicar, JP; Paine, MF; Perkins, JD; Shen, DD; Thummel, KE | 1 |
| Miller, E; Park, GR | 1 |
| Bayliss, MK; Eddershaw, PJ; Herriott, D; Manchee, GR; Park, GR; Ranshaw, LE; Tarbit, MH | 1 |
| Boulieu, R; Lehmann, B | 1 |
| Bush, E; Ghosal, A; Moore, D; Satoh, H; Thomas, PE | 1 |
| Banditt, P; Martens, J | 1 |
| Amstutz, P; Benayed, M; Benhamou, D; Bourget, P; Bouton, V; Dufieux, JL; Goursot, G; Grobuis, S; Haberer, JP; Jardin, F; Kirstetter, P; Lesne-Hulin, A; Marty, J; Mercatello, A; Page, B; Pourriat, JL; Vassal, T | 1 |
| Björkman, S; Idvall, J; Rigemar, G | 1 |
| De Winne, AJ; Desager, JP; Eeckhoudt, SL; Horsmans, Y; Verbeeck, RK | 1 |
| Fleishaker, JC; Hopkins, NK; Pearson, LK; Pearson, PG; Peters, GR; Wienkers, LC | 1 |
| Danhof, M; Herben, VM; Mandema, JW; Tuk, B; van Oostenbruggen, MF | 1 |
| Calamia, JC; Fisher, JM; Kunze, KL; Schmiedlin-Ren, P; Shen, DD; Thummel, KE; Watkins, PB; Wrighton, SA | 1 |
| Calamia, JC; Fisher, JM; Kunze, KL; Shen, DD; Thummel, KE; Wrighton, SA | 1 |
| Ahonen, J; Neuvonen, PJ; Olkkola, KT; Takala, A | 1 |
| Baudin, O; Dupuy, JL; François, B; Gaulier, JM; Lacassie, E; Lachâtre, G; Marquet, P | 1 |
| Haefeli, WE; Hotz, MA; Linder, L; Ritz, R; Scollo-Lavizzari, G | 1 |
| Backman, JT; Kivistö, KT; Neuvonen, PJ; Wang, JS | 1 |
| Bastien, O; Bolon, M; Boulieu, R; Flamens, C; Paulus, S | 1 |
| Brekelmans, GJ; de Haan, GJ; Edelbroek, PM; Jonker, DM; Knoester, PD; Van Der Hoeven, RT; Vermeij, TA | 1 |
| Chen, YL; Eerkes, A; Jiang, X; Magis, L; Naidong, W; Shou, WZ; Tang, YQ | 1 |
| Andersen, V; Larsen, NE; Larsen, S; Pedersen, N; Sonne, J | 1 |
| Bertino, JS; Choo, EF; Kashuba, AD; Nafziger, AN; Rocci, ML; Rogers, JF; Streetman, DS; Wilkinson, GR | 1 |
| Goddard, JM; Johnson, TN; Rostami-Hodjegan, A; Tanner, MS; Tucker, GT | 1 |
| Huang, JD; Shih, PS | 1 |
| Gregory, A; Lennard, MS; Rostami-Hodjegan, A; Shiran, MR; Tucker, GT | 1 |
| Bastien, O; Bolon, M; Boulieu, R; Flamens, C; Lehot, JJ | 1 |
| Christiansen, T; Ilondo, MM; Olsen, AK; Rasmussen, MH; Schulz, R; Taub, ME; Thomsen, MS; Zdravkovic, M | 1 |
| Chen, GL; Chen, XP; Huang, SL; Liu, ZQ; Ou-Yang, DS; Tan, ZR; Wang, LS; Zhou, HH; Zhu, B | 1 |
| Chua, C; Fan, L; Goh, BC; Khoo, YM; Lee, HS; Lim, R; Ong, AB; Wang, L | 1 |
| Akiyama, TE; Cheung, C; Elizondo, G; Feigenbaum, L; Gonzalez, FJ; Granvil, CP; Krausz, KW; Yu, AM | 1 |
| de Hoog, M; de Wildt, SN; van den Anker, JN; van der Giesen, E; Vinks, AA | 1 |
| Chen, XP; Huang, P; Huang, SL; Ouyang, DS; Wang, LS; Zhou, HH; Zhu, B | 1 |
| Fukuoka, M; Hirano, M; Hirata, K; Kurokawa, A; Matsumoto, Y; Onda, M; Shimizu, M; Yamamoto, Y | 1 |
| Baumann, P; Bouchoux, G; Eap, CB; Powell Golay, K | 1 |
| Aubert, AC; Baumann, P; Bleiber, G; Buclin, T; Cucchia, G; Eap, CB; Golay, KP; Hustert, E; Kerb, R; Telenti, A; Zullino, D | 1 |
| Aubert, AC; Baumann, P; Bleiber, G; Buclin, T; Eap, CB; Golay, KP; Hustert, E; Kerb, R; Telenti, A | 1 |
| Inoue, Y; Tateishi, T; Yasui-Furukori, N | 1 |
| Baumann, P; Buclin, T; Decosterd, L; Eap, CB; Fellay, J; Golay, KP; Marzolini, C; Telenti, A | 1 |
| Hall, SD; Jones, DR; Wang, YH | 1 |
| Davies, G; Hilton, PJ; McKenzie, CA; McKinnon, W; Naughton, DP; Phillips, GJ; Treacher, D | 1 |
| Edwards, G; Kokwaro, GO; Muchohi, SN; Newton, CR; Preston, L; Ward, SA | 1 |
| Bellmann, R; Joannidis, M; Kountchev, J | 1 |
| Bonato, PS; Coelho, EB; Dos Santos, NA; Jabor, VA; Lanchote, VL | 1 |
| Frerichs, VA; Haas, CE; Zaranek, C | 1 |
| Briellmann, TA; Dussy, FE; Hamberg, C | 1 |
| Allen, KE; Cameron, MD; Campbell, AP; Kunze, KL; Nelson, SD; Roberts, AG; Schuman, JT; Wen, B | 1 |
| Baumgartner, A; Halwachs-Baumann, G; März, W; Meinitzer, A; Zink, M | 1 |
| Danhof, M; de Jongh, J; Strack van Schijndel, RM; Swart, EL; Thijs, LG; Zuideveld, KP | 1 |
| Brennan, BJ; Brown, AB; Davies, BE; Gooden, C; Kolis, SJ; Rutman, O | 1 |
| Bertino, JS; Lee, LS; Nafziger, AN | 1 |
| Kanazawa, H; Murakami, I; Shimizu, M; Sugawara, K; Tamura, HO; Tateishi, T; Uno, T | 1 |
| Haschke, M; Krähenbühl, S; Link, B; Wenk, M | 1 |
| Li, W; Luo, S; Smith, HT; Tse, FL | 1 |
| Jeong, HE; Kang, W; Lee, SJ; Lee, SS; Liu, KH; Park, YJ; Ryu, JY; Shin, CM; Shin, JG; Shon, JH; Sunwoo, YE | 1 |
| Bachmakov, I; Bremer, F; Fromm, MF; König, J; Schüttler, J; Schwilden, H | 1 |
| Bettenhausen, DK; Connolly, M; Forbes, WP; Pentikis, HS; Trapnell, CB | 1 |
| Bush, D; Doss, GA; Franklin, RB; Vincent, S; Xu, S; Zhu, B | 1 |
| Fan, Z; Huang, J; Jiang, L; Li, G; Qiu, J; Si, L | 1 |
| Cao, L; Li, G; Mao, X; Qiu, J; Ren, X; Schimmer, AD; Si, L; Xiong, H | 1 |
| Cao, L; Li, G; Qiu, J; Ren, XH; Si, LQ; Yao, J | 1 |
| Foti, RS; Pearson, JT; Rock, DA | 1 |
| Inui, N; Kagawa, Y; Kokudai, M; Sakaeda, T; Takeuchi, K; Watanabe, H | 1 |
| Cheng, ZN; Hu, ZY; Wu, D; Zhao, YS | 1 |
| Frye, RF; Himmelfarb, J; Le, P; Leblond, FA; Naud, J; Nolin, TD; Pichette, V; Sadr, H | 1 |
| Cheng, ZN; Hu, ZY; Li, XM; Luo, X | 1 |
| Burnett, JR; Clarke, MW; Croft, KD; Hodgson, JM; Ledowski, T; Puddey, IB; Wu, JH | 1 |
| Chang, YZ; Chu, QJ; Kan, QC; Li, ZS; Lu, H; Wang, ZY; Zhang, J; Zhang, LR; Zhang, W | 1 |
| Hofmann, C; Patel, A; Riek, M; Schmitt, C; Zwanziger, E | 1 |
| Ishii, M; Iwasaki, T; Nonoda, Y; Osawa, M | 1 |
| Hu, ZY; Zhao, YS | 1 |
| Bies, RR; Callaway, CW; Empey, PE; Hostler, D; Kochanek, PM; Poloyac, SM; Rittenberger, JC; Tortorici, MA; Zhou, J | 1 |
| Amin, J; Bell, L; Bickford, S; Brown, A; Harriman, S; Hatsis, P | 1 |
| Akhlaghi, F; Chitnis, SD; Dostalek, M; Ionita, IA; Macwan, JS | 1 |
| Baba, K; Hamahata, Y; Hayashi, M; Iwanaga, K; Kakemi, M; Miyazaki, M; Shibano, M; Taniguchi, M | 1 |
| Ahsman, MJ; Hanekamp, M; Mathot, RA; Tibboel, D; Wildschut, ED | 1 |
| Katzenmaier, S; Markert, C; Mikus, G | 1 |
| Bae, SK; Choi, CS; Choi, YK; Liu, KH; Seo, KA; Shin, JG | 1 |
| Burhenne, J; Fetzner, L; Haefeli, WE; Mikus, G; Unger, M; Völker, M; Weiss, J | 1 |
| de Jonge, H; de Loor, H; Kuypers, DR; Vanrenterghem, Y; Verbeke, K | 1 |
| Chen, L; de Boer, T; den Daas, I; Meulman, E; Renkema, G; Reuvers, M; van Iersel, T; Wemer, J; Wieling, J | 1 |
| Bi, H; Huang, L; Huang, M; Qin, X; Xiao, H; Xue, X; Zhong, G | 1 |
| Jarho, P; Kaartama, R; Kokki, H; Lehtonen, M; Savolainen, J | 1 |
| Duan, KM; Mao, YM; Ouyang, W; Wang, SY; Yang, LJ | 1 |
| Li, WL; Su, MW; Xin, HW | 1 |
| Atkins, WM; Halpert, JR; Nelson, SD; Roberts, AG; Thummel, KT; Yang, J | 1 |
| Hansson, GP; Sennbro, CJ; Svanström, C; Svensson, LD | 1 |
| Azerad, R; Denoux, M; Marvalin, C; Pérard, S; Roy, S | 1 |
| Atkins, WM; Isoherranen, N; Paine, MF; Thummel, KE; Yang, J | 1 |
| Alves, K; Chandorkar, G; Farmer, HF; Garg, V; Smith, F; van Heeswijk, RP | 1 |
| Hutchison, M; Morikawa, Y; Pickup, K; Samuelsson, K; Sarda, S; Schulz-Utermoehl, T; Swales, JG; Wilson, ID | 1 |
| Chalasani, N; Gorski, JC; Hall, SD; Hamman, MA; Malireddy, SR; Quinney, SK; Vuppalanchi, R | 1 |
| Atzrodt, J; Blankenstein, J; Brasseur, D; Calvo-Vicente, S; Denoux, M; Derdau, V; Lavisse, M; Perard, S; Roy, S; Sandvoss, M; Schofield, J; Zimmermann, J | 1 |
| Burhenne, J; Fuchs, I; Haefeli, WE; Hafner-Blumenstiel, V; Markert, C; Mikus, G; Weiss, J | 1 |
| Bouillaud, E; Cheung, W; Delaney, R; Jappe, A; Urva, S | 1 |
| Bartkowska-Sniatkowska, A; Bienert, A; Grześkowiak, E; Grześkowiak, M; Kaliszan, R; Rosada-Kurasińska, J; Sokołowska, A; Teżyk, A; Wiczling, P; Zaba, C | 1 |
| Beijnen, JH; Maas-Bakker, RF; Meijerman, I; Mooiman, KD; Rosing, H; Schellens, JH | 1 |
| Gallagher, R; Grimsley, A; Hutchison, M; Pickup, K; Samuelsson, K; Wilson, ID | 1 |
| Blotner, S; Brennan, BJ; Morcos, PN; Moreira, SA; Shulman, NS; Smith, PF | 1 |
| Burhenne, J; Haefeli, WE; Lausecker, B; Mikus, G; Stoll, F; Thomsen, T; Weiss, J | 1 |
| Akamatsu, T; Chida, K; Inui, N; Karayama, M; Namiki, N; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Goh, BC; Hee, KH; Lee, LS; Sapari, NS; Seng, KY; Soon, GH; Soong, R | 1 |
| Junghaenel, S; Mueller, C; Roth, B; Weiss, V; Welzing, L; Wiesen, MH | 1 |
| Chen, X; Deng, S; Fan, A; Gao, W; Li, C; Li, N; Liu, Q; Wang, C; Wen, X; Zhang, Q; Zhang, W; Zhang, Y; Zhao, D; Zhao, J | 1 |
| Di Gion, P; Frechen, S; Fuhr, U; Kerkweg, U; Kraus, D; Queckenberg, C; Rokitta, D; Suleiman, AA; Tomalik-Scharte, D | 1 |
| Henion, J; Oliveira, RV; Wickremsinhe, ER | 1 |
| Kosugi, Y; Takahashi, J | 1 |
| Scheen, AJ; Stockis, A; Watanabe, S | 1 |
| He, F; Huang, S; Liu, M; Xia, C; Xiong, Y; Zeng, C; Zhang, H; Zhang, W | 1 |
| Groeneveld, GJ; Guan, Z; Klaassen, ES; Merkus, FW; Schrier, L; Tuk, B; van der Geest, R; van Gerven, JM; Zuiker, R | 1 |
| Baar, FPM; de Winter, BCM; Franken, LG; Koch, BCP; Masman, AD; Mathot, RAA; Tibboel, D; van Gelder, T | 1 |
| Burton, I; Granier, LA; Guittet, C; Manso, M; Marçon, F | 1 |
| Antkowiak, B; Balk, M; Drexler, B; Hentschke, H; Rudolph, U | 1 |
| Ashton, M; Aziz, MY; Hoffmann, KJ | 1 |
| Cheung, LC; Lim, LY; Nguyen, MN; Salman, S; Slevin, L; Sommerfield, D; Tang, EKY; von Ungern Sternberg, BS | 1 |
| Beaudry, F; Beaufrère, H; Dutton, C; Gu, Y; Johnson, R; Larouche, CB; Mosley, C; Zaman, KA | 1 |
| Jang, IJ; Kang, H; Kim, BJ; Kim, JG; Kim, JW; Lee, SW; Park, JY | 1 |
| Berger, B; Dingemanse, J; Kaufmann, P; Koch, A | 1 |
| Aepfelbacher, J; Bunn, HT; George, JM; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; McLaughlin, M; Proschan, M; Rosenthal, E; Vijan, A | 1 |
| Li, L; Li, SL; Qiu, XJ; Xing, WB; Zhang, W; Zhao, T; Zhou, W | 1 |
| Meid, AD; Mikus, G; Wiebe, ST | 1 |
| Kawamura, F; Kubiura-Ichimaru, M; Mine, A; Okuyama, S; Ooeda, K; Tada, M; Tsuji, S; Ueyama, T; Yamashita, M | 1 |
| Drummer, OH; Duan, G; Ji, J; Shen, M; Wang, X; Xiang, P; Zhuo, Y | 1 |
| Gościniak, K; Grabowski, T; Sopata, M; Stachowiak-Szymczak, K; Teżyk, A; Zaporowska-Stachowiak, I | 1 |
| Furuie, H; Igawa, Y; Ishizuka, H; Ishizuka, T; Kato, M; Kuroda, K; Nishikawa, Y; Okuda, Y; Shimizu, T; Toyama, K | 1 |
| DuBois, B; Mehvar, R; Venkatapura Chandrashekar, D | 1 |
| de Wildt, SN; Howgate, EM; Johnson, TN; Rowland Yeo, K; Turner, MA | 1 |
1 review(s) available for 1-hydroxymethylmidazolam and midazolam
| Article | Year |
|---|---|
Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Topics: Administration, Oral; Area Under Curve; Biological Availability; Cytochrome P-450 CYP3A; Female; Humans; Injections, Intravenous; Intestinal Absorption; Male; Metabolic Clearance Rate; Midazolam; Sex Characteristics | 2010 |
45 trial(s) available for 1-hydroxymethylmidazolam and midazolam
| Article | Year |
|---|---|
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers.
Topics: Administration, Oral; Adult; Central Nervous System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Electroencephalography; Female; Humans; Infusions, Intravenous; Male; Midazolam; Models, Biological; Saccades | 1992 |
Plasma concentrations of flurazepam and midazolam in chronic insomniacs during 14-day use and their relationship to therapeutic effects and next-day performance and mood.
Topics: Adult; Arousal; Attention; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flurazepam; Humans; Male; Midazolam; Middle Aged; Neuropsychological Tests; Psychomotor Performance; Sleep Initiation and Maintenance Disorders; Sleep Stages | 1990 |
Influence of food on midazolam absorption.
Topics: Adult; Benzodiazepines; Female; Food; Humans; Intestinal Absorption; Kinetics; Male; Midazolam; Middle Aged; Random Allocation | 1986 |
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Topics: Administration, Oral; Adult; Biological Availability; Blood Proteins; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Epithelium; Female; GABA Modulators; Humans; In Vitro Techniques; Injections, Intravenous; Intestine, Small; Male; Microsomes; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Protein Binding; Regression Analysis; Sex Factors | 1996 |
Influence of acute renal failure on FPIA rapid serum assay of midazolam and its main metabolite.
Topics: Acute Kidney Injury; Adult; Aged; Anesthetics, Intravenous; Chromatography, High Pressure Liquid; Female; Fluorescence Polarization Immunoassay; Glucuronates; Humans; Hydrolysis; Male; Midazolam; Middle Aged | 1997 |
Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A.
Topics: Adolescent; Adult; Age Factors; Aged; Antioxidants; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Body Weight; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Estrogens; Female; Hormone Replacement Therapy; Humans; Metabolic Clearance Rate; Midazolam; Middle Aged; Oxidoreductases, N-Demethylating; Postmenopause; Pregnatrienes; Premenopause; Progesterone | 1999 |
Auditory and electroencephalographic effects of midazolam and alpha-hydroxy-midazolam in healthy subjects.
Topics: Adult; Anti-Anxiety Agents; Audiometry, Pure-Tone; Auditory Pathways; Cross-Over Studies; Double-Blind Method; Electroencephalography; Evoked Potentials, Auditory, Brain Stem; Humans; Male; Midazolam; Respiratory Mechanics | 2000 |
Effects of metronidazole on midazolam metabolism in vitro and in vivo.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Male; Metronidazole; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Psychomotor Performance | 2000 |
Midazolam disposition in patients undergoing continuous venovenous hemodialysis.
Topics: Aged; Anuria; Area Under Curve; Chromatography, High Pressure Liquid; Critical Care; Female; Glucuronides; Half-Life; Hemofiltration; Humans; Hypnotics and Sedatives; Kidney Function Tests; Male; Midazolam; Middle Aged; Ultrafiltration | 2001 |
Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.
Topics: Administration, Intranasal; Adult; Anti-Anxiety Agents; Biological Availability; Cross-Over Studies; Female; Half-Life; Humans; Injections, Intravenous; Male; Midazolam; Middle Aged; Models, Biological; Nasal Mucosa | 2002 |
Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.
Topics: Adult; Aged; Biological Availability; Citrus; Cross-Over Studies; Cytochrome P-450 Enzyme System; Female; Food-Drug Interactions; Humans; Hypnotics and Sedatives; Intestinal Mucosa; Liver Cirrhosis; Male; Midazolam; Middle Aged | 2002 |
[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics].
Topics: Adjuvants, Anesthesia; Aged; Biotransformation; Chromatography, Liquid; Female; Half-Life; Hemofiltration; Humans; Liver Failure; Male; Midazolam; Middle Aged; Multiple Organ Failure; Renal Insufficiency | 2002 |
A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.
Topics: Adjuvants, Anesthesia; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dipeptides; Drug Interactions; Half-Life; Humans; Male; Midazolam; Middle Aged; Time Factors | 2003 |
Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Enzyme Induction; Female; Humans; Ketoconazole; Male; Midazolam; Middle Aged; Oxidoreductases, N-Demethylating | 2004 |
Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.
Topics: Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Male; Midazolam | 2004 |
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Enzyme Activation; Female; HIV Infections; Humans; Male; Midazolam; Middle Aged; Oxidoreductases, N-Demethylating; Phenotype | 2005 |
Analysis of omeprazole, midazolam and hydroxy-metabolites in plasma using liquid chromatography coupled to tandem mass spectrometry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aryl Hydrocarbon Hydroxylases; Calibration; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Humans; Injections, Intravenous; Mass Spectrometry; Midazolam; Mixed Function Oxygenases; Omeprazole; Reproducibility of Results; Time Factors | 2005 |
Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Chromatography, High Pressure Liquid; Conscious Sedation; Critical Illness; Female; Humans; Hypnotics and Sedatives; Infusions, Intravenous; Inpatients; Intensive Care Units; Lorazepam; Male; Midazolam; Middle Aged; Models, Biological; Respiration, Artificial | 2006 |
Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men.
Topics: Adult; Area Under Curve; Biotransformation; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Emphysema; Half-Life; Humans; Hypnotics and Sedatives; Male; Midazolam; Pyrazoles | 2006 |
Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.
Topics: Adult; Algorithms; Area Under Curve; Biotransformation; Cytochrome P-450 CYP3A; Humans; Hypnotics and Sedatives; Midazolam; Prospective Studies; Reproducibility of Results | 2006 |
Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation.
Topics: Aged; Conscious Sedation; Critical Care; Cytochrome P-450 CYP3A; Drug Monitoring; Genotype; Humans; Hypnotics and Sedatives; Midazolam; Middle Aged | 2007 |
The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anti-Anxiety Agents; Anti-Infective Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP3A; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Intestines; Liver; Male; Midazolam; Middle Aged; Rifamycins; Rifaximin | 2007 |
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Japan; Male; Midazolam; Pyrroles; Quinolines; Simvastatin | 2009 |
Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.
Topics: Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Humans; Hydrocortisone; Male; Midazolam; Young Adult | 2009 |
Vitamin E supplementation and hepatic drug metabolism in humans.
Topics: Adult; alpha-Tocopherol; Area Under Curve; Biotransformation; Chromans; Cytochrome P-450 CYP3A; Dietary Supplements; Double-Blind Method; Drug Interactions; Female; gamma-Tocopherol; Humans; Liver; Male; Midazolam; Middle Aged; Pharmaceutical Preparations; Propionates; Vitamin E | 2009 |
Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers.
Topics: Adult; Area Under Curve; Body Temperature; Computer Simulation; Cross-Over Studies; Cytochrome P-450 CYP3A; Heart Rate; Humans; Hypothermia; Infusions, Intravenous; Magnesium Sulfate; Male; Midazolam; Models, Biological; Pharmacokinetics; Sodium Chloride; Temperature; Young Adult | 2010 |
Daily honey consumption does not change CYP3A activity in humans.
Topics: Administration, Oral; Adult; Biological Availability; Biotransformation; Body Mass Index; Cytochrome P-450 CYP3A; Female; Flavonoids; Food-Drug Interactions; Half-Life; Honey; Humans; Injections, Intravenous; Intestines; Liver; Male; Metabolic Clearance Rate; Midazolam; Single-Blind Method; Young Adult | 2011 |
Effect of quercetin on CYP3A activity in Chinese healthy participants.
Topics: Adult; Alleles; China; Cross-Over Studies; Cytochrome P-450 CYP3A; Dietary Supplements; Enzyme Induction; Food-Drug Interactions; Gene Frequency; Genetic Association Studies; Half-Life; Humans; Male; Metabolic Detoxication, Phase I; Midazolam; Polymorphism, Single Nucleotide; Quercetin; Young Adult | 2012 |
Effect of telaprevir on the pharmacokinetics of midazolam and digoxin.
Topics: Adolescent; Adult; Antiviral Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Oligopeptides; Protease Inhibitors; Young Adult | 2012 |
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.
Topics: Administration, Oral; Adult; Analysis of Variance; Biopsy; Biotransformation; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Duodenum; Enzyme Inhibitors; Female; Genotype; Humans; Hydroxylation; Liver; Male; Midazolam; Middle Aged; Phenotype; Substrate Specificity; Young Adult | 2013 |
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.
Topics: Adult; Area Under Curve; Biotransformation; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Germany; Humans; Hydroxylation; Hypericum; Ketoconazole; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Plant Extracts; Plants, Medicinal; Pregnane X Receptor; Receptors, Steroid; Substrate Specificity; Transcription, Genetic; Young Adult | 2013 |
A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects.
Topics: Adult; Anti-Anxiety Agents; Drug Interactions; Everolimus; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; Male; Midazolam; Middle Aged; Sirolimus; Young Adult | 2013 |
Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children.
Topics: Adolescent; Blood Pressure; Body Temperature; Body Weight; Cardiac Output; Child; Child, Preschool; Circadian Rhythm; Critical Illness; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hypnotics and Sedatives; Infant; Infusions, Intravenous; Intensive Care Units, Pediatric; Male; Midazolam; Models, Biological; Nonlinear Dynamics; Respiration, Artificial; Time Factors | 2013 |
Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Least-Squares Analysis; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Young Adult | 2013 |
Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Female; Humans; Male; Midazolam; Middle Aged; Ritonavir; Simvastatin | 2013 |
CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
Topics: Adult; Aged; Anti-Anxiety Agents; Asian People; Bilirubin; Body Weight; Creatinine; Cytochrome P-450 CYP3A; Female; Genotype; Glucuronosyltransferase; Humans; Injections, Intravenous; Male; Midazolam; Middle Aged; Neoplasms; Polymorphism, Genetic | 2014 |
Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam.
Topics: Adult; Circadian Rhythm; Cytochrome P-450 CYP3A; Female; Humans; Infusions, Intravenous; Liver; Male; Midazolam; Models, Biological; Nonlinear Dynamics; Young Adult | 2014 |
Effect of brivaracetam on CYP3A activity, measured by oral midazolam.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Humans; Male; Midazolam; Middle Aged; Pyrrolidinones; Young Adult | 2015 |
Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation.
Topics: Administration, Intranasal; Administration, Intravenous; Adult; Biological Availability; Conscious Sedation; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Nasal Mucosa; Reaction Time; Young Adult | 2017 |
Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Glomerular Filtration Rate; Humans; Hypnotics and Sedatives; Hypoalbuminemia; Injections, Subcutaneous; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Nonlinear Dynamics; Palliative Care; Precision Medicine; Renal Elimination; Terminally Ill; Time Factors | 2017 |
A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).
Topics: Administration, Oral; Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Female; gamma-Cyclodextrins; Half-Life; Humans; Hypnotics and Sedatives; Injections, Intravenous; Male; Midazolam; Middle Aged; Pharmaceutical Vehicles | 2017 |
A novel, palatable paediatric oral formulation of midazolam: pharmacokinetics, tolerability, efficacy and safety.
Topics: Administration, Oral; Biotransformation; Child; Child, Preschool; Chocolate; Drug Compounding; Female; Humans; Hypnotics and Sedatives; Infant; Male; Midazolam; Nurses; Parents; Patient Safety; Preanesthetic Medication; Prospective Studies; Single-Blind Method; Taste | 2018 |
Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
Topics: Adult; Area Under Curve; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Healthy Volunteers; Humans; Hydrocortisone; Male; Midazolam; Middle Aged; Orexin Receptor Antagonists; Orexin Receptors; Young Adult | 2020 |
The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults.
Topics: Administration, Oral; Adult; Aldehyde Dehydrogenase; Area Under Curve; Cytochrome P-450 CYP3A; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Healthy Volunteers; Humans; Male; Midazolam; Organic Chemicals; Prodrugs | 2020 |
Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Cytochrome P-450 CYP3A; Drug Interactions; Half-Life; Humans; Hypnotics and Sedatives; Male; Midazolam; Mineralocorticoid Receptor Antagonists; Pyrroles; Sulfones; Young Adult | 2021 |
113 other study(ies) available for 1-hydroxymethylmidazolam and midazolam
| Article | Year |
|---|---|
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Male; Mice; Oxidoreductases, N-Demethylating; Pharmacokinetics; Substrate Specificity | 1999 |
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Topics: Amiodarone; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Daunorubicin; Digoxin; Enzyme Inhibitors; GABA Modulators; Gonadal Steroid Hormones; Humans; LLC-PK1 Cells; Midazolam; Mixed Function Oxygenases; Nifedipine; Phthalazines; Swine; Testosterone | 2001 |
The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients.
Topics: Acute Kidney Injury; Critical Illness; Female; Glucuronates; Humans; Infusions, Intravenous; Male; Midazolam; Middle Aged; Respiration, Artificial | 1991 |
Solid-phase extraction of midazolam and two of its metabolites from plasma for high-performance liquid chromatographic analysis.
Topics: Chromatography, High Pressure Liquid; Humans; Midazolam | 1991 |
In vitro forecasting of drugs which may interfere with the biotransformation of midazolam.
Topics: Biotransformation; Debrisoquin; Humans; Hydroxylation; Male; Microsomes, Liver; Midazolam; Middle Aged; Time Factors | 1991 |
[Drug interactions of midazolam].
Topics: Biotransformation; Drug Interactions; Humans; Hydroxylation; In Vitro Techniques; Male; Microsomes, Liver; Midazolam; Middle Aged | 1989 |
The pharmacokinetics of midazolam following orthotopic liver transplantation.
Topics: Adolescent; Adult; Female; Half-Life; Humans; Liver Transplantation; Male; Midazolam; Middle Aged | 1989 |
Extra-hepatic metabolism of midazolam.
Topics: Adult; Female; Humans; Liver Function Tests; Liver Transplantation; Male; Midazolam; Middle Aged | 1989 |
Determination of midazolam and the alpha-hydroxy metabolite by gas chromatography in small plasma volumes.
Topics: Animals; Chromatography, Gas; Hydrogen-Ion Concentration; Male; Microchemistry; Midazolam; Rats; Rats, Inbred Strains | 1989 |
Plasma concentrations and pharmacokinetics of midazolam during anaesthesia.
Topics: Adolescent; Adult; Anesthesia; Chromatography, Gas; Female; Humans; Kinetics; Male; Midazolam; Middle Aged; Radioligand Assay | 1986 |
Dose dependent pharmacokinetics of midazolam.
Topics: Adult; Anesthetics; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Hypnotics and Sedatives; Kinetics; Male; Midazolam; Middle Aged | 1985 |
Measurement of midazolam and alpha-hydroxymidazolam by gas chromatography with electron-capture detection.
Topics: Animals; Benzodiazepines; Chemical Phenomena; Chemistry; Chromatography, Gas; Electrochemistry; Female; Guinea Pigs; Midazolam; Pregnancy | 1986 |
No evidence of a genetic polymorphism in the oxidative metabolism of midazolam.
Topics: Age Factors; Alcohol Drinking; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Oxidation-Reduction; Polymorphism, Genetic; Smoking | 1988 |
Rapid and sensitive high-performance liquid chromatographic assay for midazolam and 1-hydroxymidazolam, the major metabolite, in human serum.
Topics: Chromatography, High Pressure Liquid; Humans; Midazolam; Spectrophotometry, Ultraviolet | 1988 |
Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration.
Topics: Administration, Rectal; Adult; Biological Availability; Half-Life; Humans; Injections, Intravenous; Male; Midazolam | 1988 |
Failure of critically ill patients to metabolise midazolam.
Topics: Aged; Critical Care; Female; Humans; Hypnotics and Sedatives; Kinetics; Male; Midazolam; Middle Aged; Prospective Studies; Shock, Septic; Time Factors | 1987 |
Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation.
Topics: Adult; Humans; Kinetics; Liver; Midazolam; Oxidation-Reduction; Polymorphism, Genetic; Sparteine | 1986 |
Quantitation by gas chromatography of the 1- and 4-hydroxy metabolites of midazolam in human plasma.
Topics: Benzodiazepines; Chromatography, Gas; Female; Gas Chromatography-Mass Spectrometry; Humans; Hydroxylation; Kinetics; Midazolam | 1984 |
Placental transfer of midazolam and its metabolite 1-hydroxymethylmidazolam in the pregnant ewe.
Topics: Anesthesia, Obstetrical; Anesthetics; Animals; Benzodiazepines; Female; Fetal Blood; Half-Life; Kinetics; Maternal-Fetal Exchange; Midazolam; Pregnancy; Sheep | 1984 |
Prolonged sedation due to accumulation of conjugated metabolites of midazolam.
Topics: Aged; Aged, 80 and over; Animals; Coma; Electroencephalography; Female; Flumazenil; Glucuronates; Humans; Liver Function Tests; Male; Midazolam; Middle Aged; Prospective Studies; Rats; Receptors, GABA-A; Renal Insufficiency | 1995 |
Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.
Topics: Chromatography, High Pressure Liquid; Cimetidine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Erythromycin; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Midazolam; Nifedipine; Nizatidine | 1994 |
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.
Topics: Cyclosporine; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Liver; Liver Transplantation; Metabolic Clearance Rate; Midazolam; Mixed Function Oxygenases | 1994 |
Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.
Topics: Adolescent; Adult; Child; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Liver; Liver Transplantation; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Phenytoin; Tissue Donors | 1994 |
Determination of midazolam and two of its metabolites in human plasma by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Hydroxylation; Midazolam; Sensitivity and Specificity | 1994 |
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
Topics: Biotransformation; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Fetus; Humans; Isoenzymes; Kinetics; Microsomes, Liver; Midazolam; Mixed Function Oxygenases | 1994 |
Determination of midazolam and its alpha-hydroxy metabolite in human plasma and urine by high-performance liquid chromatography.
Topics: Benzodiazepinones; Chromatography, High Pressure Liquid; Humans; Midazolam; Spectrophotometry, Ultraviolet | 1993 |
Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro.
Topics: 1-Naphthylamine; Catalysis; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Fluoxetine; Humans; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Selective Serotonin Reuptake Inhibitors; Sertraline | 1995 |
In vitro inhibition of midazolam and quinidine metabolism by flavonoids.
Topics: Anti-Arrhythmia Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Flavonoids; Humans; Kinetics; Midazolam; Mixed Function Oxygenases; Quinidine | 1995 |
What changes drug metabolism in critically ill patients?--II Serum inhibits the metabolism of midazolam in human microsomes.
Topics: Aged; Anti-Anxiety Agents; Critical Illness; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Infant; Male; Microsomes, Liver; Midazolam; Middle Aged; Mixed Function Oxygenases | 1996 |
First-pass metabolism of midazolam by the human intestine.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Cytochrome P-450 Enzyme System; Female; Humans; Intestinal Mucosa; Liver Transplantation; Male; Midazolam; Middle Aged | 1996 |
What changes drug metabolism in critically ill patients--III? Effect of pre-existing disease on the metabolism of midazolam.
Topics: Adult; Biotransformation; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Graft Rejection; Humans; Hypnotics and Sedatives; Liver; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Liver Transplantation; Microsomes; Midazolam; Middle Aged; Mixed Function Oxygenases | 1996 |
The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.
Topics: Adrenergic beta-Agonists; Albuterol; Biomarkers; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Disulfiram; Humans; Isoenzymes; Ketoconazole; Microsomes, Liver; Midazolam; Molecular Structure; Oxidation-Reduction; Quinidine; Recombinant Proteins; Salmeterol Xinafoate; Sulfaphenazole; Theophylline | 1996 |
Determination of midazolam and its unconjugated 1-hydroxy metabolite in human plasma by high-performance liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Midazolam; Reproducibility of Results; Sensitivity and Specificity | 1995 |
Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Topics: Anesthetics, Intravenous; Animals; Anti-Anxiety Agents; Antibodies; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Humans; In Vitro Techniques; Kinetics; Male; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Oxidoreductases, N-Demethylating; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Recombinant Proteins | 1996 |
Simultaneous determination of midazolam and its metabolites 1-hydroxymidazolam and 4-hydroxymidazolam in human serum using gas chromatography-mass spectrometry.
Topics: Anesthetics, Intravenous; Gas Chromatography-Mass Spectrometry; Humans; Hypnotics and Sedatives; Midazolam; Sensitivity and Specificity | 1997 |
Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients.
Topics: Absorption; Administration, Intranasal; Adult; Anti-Anxiety Agents; Biological Availability; Cross-Over Studies; Female; Humans; Male; Midazolam; Middle Aged; Nasal Mucosa | 1997 |
Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography.
Topics: Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Evaluation Studies as Topic; Humans; Midazolam; Oxidoreductases, N-Demethylating; Rifampin; Sensitivity and Specificity | 1998 |
Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam.
Topics: Algorithms; Animals; Anti-Anxiety Agents; Blood Proteins; Drug Interactions; Electroencephalography; Male; Midazolam; Models, Biological; Protein Binding; Rats; Rats, Wistar | 1999 |
First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers.
Topics: Biotransformation; Blood Proteins; Blotting, Western; Caco-2 Cells; Calcitriol; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Electric Conductivity; Extracellular Space; Humans; Kinetics; Midazolam; Mixed Function Oxygenases; Permeability; Reproducibility of Results | 1999 |
Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding.
Topics: Algorithms; Caco-2 Cells; Electric Conductivity; Extracellular Matrix Proteins; Extracellular Space; Humans; Hydroxylation; Midazolam; Protein Binding; Serum Albumin | 1999 |
Interaction between fluconazole and midazolam in intensive care patients.
Topics: Adult; Analysis of Variance; Antifungal Agents; Critical Care; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fluconazole; Follow-Up Studies; Humans; Hypnotics and Sedatives; Infusions, Intravenous; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Positive-Pressure Respiration; Renal Insufficiency | 1999 |
Sensitive and specific determination of midazolam and 1-hydroxymidazolam in human serum by liquid chromatography-electrospray mass spectrometry.
Topics: Anesthetics, Intravenous; Chromatography, Liquid; Humans; Hypnotics and Sedatives; Mass Spectrometry; Midazolam; Respiration, Artificial; Sensitivity and Specificity | 1999 |
Ultrafast liquid chromatography/tandem mass spectrometry bioanalysis of polar analytes using packed silica columns.
Topics: Animals; Chromatography, Liquid; Humans; Macaca fascicularis; Midazolam; Morphine; Morphine Derivatives; Reproducibility of Results; Sensitivity and Specificity; Silicon Dioxide; Solvents; Spectrum Analysis | 2002 |
Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects.
Topics: Adult; Aged; Area Under Curve; Female; Humans; Hypnotics and Sedatives; Injections, Intravenous; Male; Metabolic Clearance Rate; Midazolam; Multicenter Studies as Topic | 2002 |
Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis.
Topics: Administration, Oral; Child, Preschool; Consciousness; Female; Humans; Hypnotics and Sedatives; Infant; Male; Midazolam; Preoperative Care | 2002 |
Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.
Topics: Area Under Curve; Asian People; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Genotype; Humans; Male; Midazolam; Taiwan | 2002 |
Determination of midazolam and 1'-hydroxymidazolam by liquid chromatography-mass spectrometry in plasma of patients undergoing methadone maintenance treatment.
Topics: Adjuvants, Anesthesia; Anti-Anxiety Agents; Chromatography, Liquid; Humans; Mass Spectrometry; Methadone; Midazolam; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 2003 |
The distribution and gender difference of CYP3A activity in Chinese subjects.
Topics: Administration, Oral; Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; China; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Female; Humans; Male; Menstrual Cycle; Midazolam; Oxidoreductases, N-Demethylating; Sex Characteristics | 2003 |
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Asia; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Female; Half-Life; Humans; Infusions, Intravenous; Male; Midazolam; Middle Aged; Neoplasms; Oxidoreductases, N-Demethylating; Phenotype | 2003 |
Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Blotting, Southern; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Drug Interactions; Enzyme Inhibitors; Half-Life; Humans; In Vitro Techniques; Intestine, Small; Ketoconazole; Male; Mice; Mice, Transgenic; Microsomes; Midazolam; Polymerase Chain Reaction; Rifampin; Time Factors | 2003 |
Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
Topics: Adolescent; Aryl Hydrocarbon Hydroxylases; Bayes Theorem; Child; Child, Preschool; Conscious Sedation; Critical Care; Cytochrome P-450 CYP3A; Female; Humans; Hypnotics and Sedatives; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Liver Failure; Male; Mathematical Computing; Metabolic Clearance Rate; Midazolam; Oxidoreductases, N-Demethylating; Renal Insufficiency | 2003 |
Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women.
Topics: Aryl Hydrocarbon Hydroxylases; Asian People; Breast Neoplasms; China; Cytochrome P-450 CYP3A; Disease Susceptibility; Female; Humans; Lymphatic Metastasis; Midazolam; Oxidoreductases, N-Demethylating; Receptors, Estrogen; Receptors, Progesterone; Risk Factors | 2003 |
Possibility of influence of midazolam sedation on the diagnosis of brain death: concentrations of active metabolites after cessation of midazolam.
Topics: Adult; Aged; Brain Death; Female; Humans; Hypnotics and Sedatives; Kidney; Male; Midazolam; Middle Aged; Monitoring, Physiologic; Time Factors | 2003 |
Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry.
Topics: Gas Chromatography-Mass Spectrometry; Humans; Midazolam; Reproducibility of Results | 2004 |
Sensitive determination of midazolam and 1'-hydroxymidazolam in plasma by liquid-liquid extraction and column-switching liquid chromatography with ultraviolet absorbance detection and its application for measuring CYP3A activity.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Female; Humans; Male; Midazolam; Oxidoreductases, N-Demethylating; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2004 |
Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Topics: Blotting, Western; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dealkylation; DNA, Complementary; Enzyme Inhibitors; Humans; Hydroxytestosterones; In Vitro Techniques; Iron; Kinetics; Microsomes, Liver; Midazolam; Stereoisomerism; Verapamil | 2005 |
Differentiating midazolam over-sedation from neurological damage in the intensive care unit.
Topics: Aged; APACHE; Hospital Mortality; Humans; Hypnotics and Sedatives; Intensive Care Units; Length of Stay; Midazolam; Middle Aged; Nervous System Diseases | 2005 |
Determination of midazolam and its major metabolite 1'-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children.
Topics: Anticonvulsants; Child; Chromatography, High Pressure Liquid; Humans; Kenya; Malaria, Falciparum; Midazolam; Reproducibility of Results; Seizures; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2005 |
Between benzodiazepine over-sedation and neurological damage.
Topics: Dose-Response Relationship, Drug; Drug Tolerance; Humans; Hypnotics and Sedatives; Midazolam; Nervous System Diseases | 2005 |
A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism.
Topics: Adult; Chromatography, Liquid; Female; Humans; Mass Spectrometry; Midazolam; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Quantification of benzodiazepines in whole blood and serum.
Topics: Anti-Anxiety Agents; Benzodiazepines; Chromatography, High Pressure Liquid; Flunitrazepam; Flurazepam; Forensic Toxicology; Humans; Mass Spectrometry; Midazolam; Molecular Structure; Serum | 2006 |
Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study.
Topics: Benzoflavones; Binding Sites; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Heme; Kinetics; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Midazolam; Protons; Testosterone | 2005 |
Midazolam and its metabolites in brain death diagnosis.
Topics: Adjuvants, Anesthesia; Adult; Anesthetics, Intravenous; Brain Death; Chromatography, High Pressure Liquid; Glucuronides; Humans; Hypnotics and Sedatives; Midazolam; Middle Aged; Tissue Donors | 2005 |
A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity.
Topics: Adult; Chromatography, Liquid; Cytochrome P-450 CYP3A; Female; Humans; Male; Mass Spectrometry; Midazolam; Molecular Structure; Reproducibility of Results | 2007 |
Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Humans; Hypnotics and Sedatives; Midazolam; Reproducibility of Results; Saliva; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2007 |
Simultaneous determination of midazolam and 1'-hydroxymidazolam in human plasma by liquid chromatography with tandem mass spectrometry.
Topics: Calibration; Chromatography, Liquid; Humans; Midazolam; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2007 |
The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals.
Topics: Adult; Anti-Anxiety Agents; Asian People; Catalysis; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Gene Frequency; Heterozygote; Humans; Isoenzymes; Kinetics; Korea; Midazolam; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Spectrophotometry | 2007 |
Characterization of 1'-hydroxymidazolam glucuronidation in human liver microsomes.
Topics: Animals; Central Nervous System Agents; Diclofenac; Glucuronides; Glucuronosyltransferase; Humans; Male; Microsomes, Liver; Midazolam; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sapogenins; Uridine Diphosphate Glucuronic Acid | 2008 |
Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Celiprolol; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Excipients; Humans; Intestinal Mucosa; Midazolam; Permeability; Poloxamer; Rats | 2008 |
Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration.
Topics: Animals; Biotransformation; Cell-Free System; Chemistry, Pharmaceutical; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenum; Enzyme Inhibitors; Excipients; Intubation, Gastrointestinal; Male; Midazolam; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Substrate Specificity | 2008 |
[Effect of polyoxyl ether analogous surfactants on the activity of cytochromes P450 3A in rats in vivo].
Topics: Animals; Area Under Curve; Biological Availability; Biotransformation; Cytochrome P-450 CYP3A; Ketoconazole; Male; Midazolam; Octoxynol; Polyethylene Glycols; Random Allocation; Rats; Rats, Sprague-Dawley; Surface-Active Agents | 2008 |
The combination of chemical and antibody inhibitors for superior P450 3A inhibition in reaction phenotyping studies.
Topics: Antibodies, Monoclonal; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxytestosterones; Ketoconazole; Microsomes, Liver; Midazolam; Protein Isoforms; Testosterone | 2008 |
Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans.
Topics: Administration, Oral; Cytochrome P-450 CYP3A; Female; Humans; Hydrocortisone; Hydroxylation; Male; Midazolam; Phenotype; Time Factors | 2009 |
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
Topics: Adult; Aged; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Urea Nitrogen; Cytochrome P-450 CYP3A; Enterocytes; Female; Hepatocytes; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Organic Anion Transporters; Prospective Studies; Rats; Rats, Sprague-Dawley; Terfenadine | 2009 |
CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients.
Topics: Alleles; Analgesia, Patient-Controlled; Analgesics, Opioid; Asian People; China; Cytochrome P-450 CYP3A; Female; Fentanyl; Gene Frequency; Genotype; Gynecologic Surgical Procedures; Humans; Infusions, Intravenous; Midazolam; Pain, Postoperative; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide | 2010 |
Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Topics: Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Combinations; Drug Interactions; Female; Half-Life; HIV Protease Inhibitors; Humans; Hypnotics and Sedatives; Male; Midazolam; Prospective Studies; Ritonavir; Saquinavir | 2009 |
Blood concentrations of midazolam in status epilepticus using an appropriate condition of HPLC.
Topics: Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Humans; Infant; Male; Midazolam; Status Epilepticus | 2010 |
High-throughput analysis of in vitro cytochrome p450 inhibition samples using mass spectrometry coupled with an integrated liquid chromatography/autosampler system.
Topics: Automation, Laboratory; Chromatography, Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; High-Throughput Screening Assays; Linear Models; Mass Spectrometry; Midazolam | 2010 |
Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1'-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry.
Topics: Chromatography, Liquid; Humans; Least-Squares Analysis; Microsomes, Liver; Midazolam; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2010 |
Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.
Topics: Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Furocoumarins; Humans; Medicine, Kampo; Midazolam; Quinidine | 2010 |
Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates.
Topics: Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; Female; Glucuronides; Half-Life; Humans; Hypnotics and Sedatives; Infant, Newborn; Male; Midazolam; Models, Biological; Nonlinear Dynamics; Time Factors; Tissue Distribution | 2010 |
Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam.
Topics: Adjuvants, Anesthesia; Administration, Oral; Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Mathematical Computing; Metabolic Clearance Rate; Midazolam; Predictive Value of Tests; Specimen Handling; Time Factors | 2010 |
Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7.
Topics: Chromatography, High Pressure Liquid; Glucuronides; Glucuronosyltransferase; Humans; Hydroxylation; In Vitro Techniques; Metabolic Detoxication, Phase II; Microsomes, Liver; Midazolam; Molecular Structure; Recombinant Proteins; Tandem Mass Spectrometry | 2010 |
A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Kidney Transplantation; Midazolam; Nonlinear Dynamics; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers.
Topics: Adult; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Stability; Female; Humans; Linear Models; Male; Midazolam; Patient Satisfaction; Phenotype; Phlebotomy; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Tandem Mass Spectrometry | 2011 |
Rapid and simultaneous measurement of midazolam, 1'-hydroxymidazolam and digoxin by liquid chromatography/tandem mass spectrometry: application to an in vivo study to simultaneously measure P-glycoprotein and cytochrome P450 3A activity.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Calibration; Cardiotonic Agents; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Stability; Limit of Detection; Male; Midazolam; Random Allocation; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
Determination of midazolam and 1-hydroxymidazolam from plasma by gas chromatography coupled to methane negative chemical ionization mass spectrometry after sublingual administration of midazolam.
Topics: Administration, Sublingual; Animals; Area Under Curve; Drug Stability; Gas Chromatography-Mass Spectrometry; Humans; Least-Squares Analysis; Male; Methane; Midazolam; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction | 2011 |
Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat.
Topics: Administration, Oral; Animals; Area Under Curve; Chromatography, High Pressure Liquid; Cyclooctanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Ketoconazole; Lignans; Male; Microsomes, Liver; Midazolam; Polycyclic Compounds; Rats; Rats, Sprague-Dawley | 2012 |
The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4.
Topics: Algorithms; Anticonvulsants; Biocatalysis; Carbamazepine; Catalytic Domain; Computer Simulation; Cytochrome P-450 CYP3A; Humans; Hydroxylation; Hypnotics and Sedatives; Kinetics; Ligands; Midazolam; Models, Molecular; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Protein Binding; Recombinant Proteins | 2011 |
Development and validation of a method using supported liquid extraction for the simultaneous determination of midazolam and 1'-hydroxy-midazolam in human plasma by liquid chromatography with tandem mass spectrometry detection.
Topics: Calibration; Chromatography, Liquid; Humans; Liquid-Liquid Extraction; Midazolam; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2012 |
Microbial production of phase I and phase II metabolites of midazolam.
Topics: Beauveria; Biotransformation; Chromatography, Liquid; Esters; Glucuronides; Humans; Magnetic Resonance Spectroscopy; Metabolic Detoxication, Phase I; Metabolic Detoxication, Phase II; Midazolam; Spectrometry, Mass, Electrospray Ionization; Streptomyces | 2012 |
Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.
Topics: Allosteric Regulation; Area Under Curve; Biomarkers; Cytochrome P-450 CYP3A; Drug Interactions; Fluconazole; Humans; Midazolam | 2012 |
Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers.
Topics: Animals; Biotransformation; Child, Preschool; Chimera; Humans; Hypnotics and Sedatives; Male; Mice; Mice, SCID; Midazolam | 2012 |
Synthesis of stable isotope labelled internal standards for drug-drug interaction (DDI) studies.
Topics: Cytochrome P-450 Enzyme System; Deuterium Exchange Measurement; Diclofenac; Isotope Labeling; Microwaves; Midazolam; Molecular Structure; Pharmaceutical Preparations; Reference Standards | 2012 |
Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures.
Topics: Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Stability; Humans; Microsomes, Liver; Midazolam; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
Topics: Animals; Bile; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Mice; Mice, Knockout; Midazolam; Troleandomycin | 2013 |
Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.
Topics: Adult; Antibiotics, Antitubercular; Asian People; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Imidazoles; Losartan; Male; Midazolam; Omeprazole; Rifampin; Tetrazoles; Theophylline; Time Factors; Withholding Treatment | 2013 |
Disposition of midazolam in asphyxiated neonates receiving therapeutic hypothermia--a pilot study.
Topics: Asphyxia Neonatorum; Biological Availability; Germany; Humans; Hypothermia, Induced; Infant, Newborn; Metabolic Clearance Rate; Midazolam; Phenylalanine; Pilot Projects; Prospective Studies; Reference Values | 2013 |
Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cytochrome P-450 CYP3A; Docetaxel; Enzyme Induction; Fatty Alcohols; Female; Gene Expression Regulation, Enzymologic; Male; Microsomes, Liver; Midazolam; Rats, Sprague-Dawley; Reproducibility of Results; Taxoids | 2014 |
Automated high-capacity on-line extraction and bioanalysis of dried blood spot samples using liquid chromatography/high-resolution accurate mass spectrometry.
Topics: Automation; Chromatography, Liquid; Dried Blood Spot Testing; Humans; Linear Models; Male; Midazolam; Models, Chemical; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2014 |
Species differences and substrate specificity of CYP3A heteroactivation by efavirenz.
Topics: Administration, Oral; Alkynes; Animals; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Interactions; Haplorhini; Humans; Hydroxylation; Male; Microsomes, Liver; Midazolam; Nifedipine; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Species Specificity; Substrate Specificity; Testosterone | 2015 |
Mechanism of Action of Panaxytriol on Midazolam 1'-Hydroxylation and 4-Hydroxylation Mediated by CYP3A in Liver Microsomes and Rat Primary Hepatocytes.
Topics: Animals; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Enediynes; Fatty Alcohols; Hepatocytes; Humans; Hydroxylation; Ketoconazole; Microsomes, Liver; Midazolam; Rats; RNA, Messenger | 2015 |
Differential depression of neuronal network activity by midazolam and its main metabolite 1-hydroxymidazolam in cultured neocortical slices.
Topics: Animals; Cells, Cultured; Female; GABA Modulators; Hypnotics and Sedatives; Male; Mice, Inbred C57BL; Mice, Transgenic; Midazolam; Neocortex; Neurons; Receptors, GABA-A | 2017 |
Inhibition of CYP3A by Antimalarial Piperaquine and Its Metabolites in Human Liver Microsomes With IVIV Extrapolation.
Topics: Antimalarials; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Humans; Microsomes, Liver; Midazolam; Quinolines; Tandem Mass Spectrometry | 2018 |
Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations.
Topics: Animals; Area Under Curve; Boidae; Central Venous Catheters; Half-Life; Hypnotics and Sedatives; Injections, Intramuscular; Midazolam | 2019 |
Influence of midazolam-related genetic polymorphism on conscious sedation during upper gastrointestinal endoscopy in a Korean population.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; Conscious Sedation; Cytochrome P-450 CYP3A; Endoscopy, Gastrointestinal; Female; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Polymorphism, Genetic; Prospective Studies; Republic of Korea; Young Adult | 2019 |
Effects of Dexmedetomidine on the Pharmacokinetics of Dezocine, Midazolam and Its Metabolite 1-Hydroxymidazolam in Beagles by UPLC-MS/MS.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, High Pressure Liquid; Dexmedetomidine; Dogs; Female; Male; Midazolam; Tandem Mass Spectrometry; Tetrahydronaphthalenes | 2020 |
Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity.
Topics: Adult; Area Under Curve; Biological Variation, Population; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Models, Biological; Sensitivity and Specificity; Young Adult | 2020 |
A two-dimensional multiwell cell culture method for the production of CYP3A4-expressing hepatocyte-like cells from HepaRG cells.
Topics: Cell Culture Techniques; Cell Differentiation; Cell Line; Cell Proliferation; Cytochrome P-450 CYP3A; Drug Evaluation, Preclinical; Gene Expression Regulation; Green Fluorescent Proteins; Hepatocytes; Humans; Microscopy, Confocal; Midazolam; Recombinant Proteins | 2020 |
Pharmacokinetic study of midazolam and α-hydroxymidazolam in guinea pig blood and hair roots after a single dose of midazolam.
Topics: Animals; Guinea Pigs; Hair; Midazolam | 2021 |
Midazolam and hydroxymidazolam plasma concentrations can be monitored with selected biochemical and physiological parameters of palliative care patients.
Topics: Adult; Aged; Aged, 80 and over; Bilirubin; Biomarkers; Body Mass Index; Creatinine; Drug Dosage Calculations; Drug Monitoring; Female; Glomerular Filtration Rate; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Models, Biological; Palliative Care; Pilot Projects; Reproducibility of Results | 2021 |
UPLC-MS/MS analysis of the Michaelis-Menten kinetics of CYP3A-mediated midazolam 1'- and 4-hydroxylation in rat brain microsomes.
Topics: Animals; Brain; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Kinetics; Male; Microsomes; Midazolam; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2021 |
Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo.
Topics: Adolescent; Adult; Child; Child, Preschool; Cytochrome P-450 CYP3A; Drug Interactions; Glucuronosyltransferase; Humans; Infant; Infant, Newborn; Liver; Midazolam; Models, Biological | 2023 |